BidaskClub downgraded shares of Clovis Oncology (NASDAQ:CLVS) from a hold rating to a sell rating in a research note published on Thursday.

A number of other equities analysts have also issued reports on CLVS. ValuEngine lowered shares of Clovis Oncology from a hold rating to a sell rating in a research report on Tuesday, April 17th. Cann reissued a hold rating on shares of Clovis Oncology in a research report on Tuesday, February 27th. SunTrust Banks reduced their price target on shares of Clovis Oncology from $95.00 to $85.00 and set a buy rating for the company in a research report on Tuesday, February 27th. Barclays set a $85.00 price target on shares of Clovis Oncology and gave the stock a buy rating in a research report on Tuesday, February 27th. Finally, Stifel Nicolaus reduced their price target on shares of Clovis Oncology from $125.00 to $110.00 and set a buy rating for the company in a research report on Tuesday, February 27th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and thirteen have assigned a buy rating to the stock. The stock presently has a consensus rating of Buy and an average price target of $87.60.

Shares of Clovis Oncology stock opened at $50.17 on Thursday. The company has a current ratio of 7.69, a quick ratio of 7.35 and a debt-to-equity ratio of 0.77. Clovis Oncology has a 52 week low of $45.42 and a 52 week high of $99.45.

Clovis Oncology (NASDAQ:CLVS) last posted its quarterly earnings results on Monday, February 26th. The biopharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.25. Clovis Oncology had a negative net margin of 624.02% and a negative return on equity of 81.34%. The company had revenue of $17.04 million during the quarter, compared to analyst estimates of $19.42 million. During the same period last year, the firm posted ($1.83) EPS. Clovis Oncology’s revenue for the quarter was up 21746.2% compared to the same quarter last year. research analysts anticipate that Clovis Oncology will post -4.67 EPS for the current fiscal year.

In related news, Director Thorlef Spickschen sold 4,500 shares of Clovis Oncology stock in a transaction on Monday, April 9th. The shares were sold at an average price of $60.02, for a total value of $270,090.00. Following the sale, the director now owns 7,618 shares of the company’s stock, valued at approximately $457,232.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Gillian C. Ivers-Read sold 3,000 shares of Clovis Oncology stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $54.09, for a total transaction of $162,270.00. Following the completion of the sale, the insider now directly owns 180,571 shares in the company, valued at approximately $9,767,085.39. The disclosure for this sale can be found here. Insiders have sold a total of 16,500 shares of company stock worth $978,975 in the last ninety days. Corporate insiders own 12.50% of the company’s stock.

Hedge funds have recently made changes to their positions in the business. Greenwood Capital Associates LLC lifted its holdings in Clovis Oncology by 21.6% in the 4th quarter. Greenwood Capital Associates LLC now owns 5,605 shares of the biopharmaceutical company’s stock valued at $381,000 after purchasing an additional 996 shares in the last quarter. Element Capital Management LLC purchased a new position in Clovis Oncology in the 4th quarter valued at $11,400,000. Rice Hall James & Associates LLC lifted its holdings in Clovis Oncology by 21.4% in the 4th quarter. Rice Hall James & Associates LLC now owns 147,650 shares of the biopharmaceutical company’s stock valued at $10,040,000 after purchasing an additional 25,985 shares in the last quarter. Wealthstreet Investment Advisors LLC purchased a new position in Clovis Oncology in the 4th quarter valued at $3,195,000. Finally, Palo Alto Investors LLC lifted its holdings in Clovis Oncology by 2.2% in the 4th quarter. Palo Alto Investors LLC now owns 3,402,781 shares of the biopharmaceutical company’s stock valued at $231,389,000 after purchasing an additional 73,200 shares in the last quarter.

COPYRIGHT VIOLATION NOTICE: This piece was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dailypolitical.com/2018/04/22/clovis-oncology-clvs-cut-to-sell-at-bidaskclub.html.

Clovis Oncology Company Profile

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

Analyst Recommendations for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.